A randomized comparison of RadIal Vs. femorAL access for coronary intervention in ACS (RIVAL) SS Jolly, S Yusuf, J Cairns, K Niemela, D Xavier, P Widimsky,

Slides:



Advertisements
Similar presentations
Impact of Anemia on One-Year Ischemic Events and Mortality Among Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention Steven.
Advertisements

Efficacy and Safety of Fondaparinux in Elderly Patients With ST-Segment Elevation Myocardial Infarction: Data From the OASIS 6 Trial Efficacy and Safety.
Stone p2203/Abstract/ Conclusions
PCI - A prospective, randomized, double- blind substudy of patients undergoing PCI in the CURE trial.
Keith A A Fox Royal Infirmary & University of Edinburgh CURE and PCI-CURE.
A randomized comparison of RadIal Vs. femorAL access for coronary intervention in ACS (RIVAL) SS Jolly, S Yusuf, J Cairns, K Niemela, D Xavier, P Widimsky,
Long-term Outcomes of Patients with ACS and Chronic Renal Insufficiency Undergoing PCI and being treated with Bivalirudin vs UFH/Enoxaparin plus a GP IIb/IIIa.
RADIAL VS FEMORAL ACCESS FOR CORONARY ANGIOGRAPHY AND INTERVENTION IN PATIENTS WITH ACS-( RIVAL) A RANDOMIZED,PARALLEL GROUP, MULTICENTRE TRIAL.
Predictors of Major Vascular Access Site Complications in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Insights.
Low vs. Standard Dose Unfractionated Heparin for Percutaneous Coronary Intervention in Acute Coronary Syndromes Patients treated with Fondaparinux: the.
on behalf of the TOTAL Investigators
TOTAL Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI TOTAL Trial Investigators.
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.
VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
An International Randomized Trial of Early Versus Delayed Invasive Strategies in Patients with Non-ST Segment Elevation Acute Coronary Syndromes TIMACS.
Hamon M 1, Nienaber C 2, Galli S 3, Huber K 4, Gulba D 5, Hill J 6, Lafont A 7, Cequier A 8, Bernstein D 9, Deliargyris E 9 Institutions: 1. Centre Hospitalier.
1 Incidence, impact and preventative strategies for non- access site bleeding in the PCI patient Martial Hamon. MD. FESC University Hospital. Caen. France.
BLEEDING AND ACUTE CORONARY SYNDROMES Cardiac Catherization Conference Syed Raza MD Cardiology Fellow VCU Medical Center 06/02/2011.
OASIS 5 Access AHA 2006 Martial Hamon, Shamir Mehta, Gabriel Steg, David Faxon, Prafulla Kerkar, Hans-Jürgen Rupprecht, Jean-Francois Tanguay, Rizwan Afzal,
Sunil V. Rao MD The Duke Clinical Research Institute The Durham VA Medical Center Duke University Medical Center Transradial PCI in Octogenarians: Caveats,
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University Hamilton, CANADA on behalf of the CORONARY Investigators Disclosures.
André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University Hamilton, CANADA on behalf of the CORONARY Investigators Disclosures.
TRI vs TFI in STEMI Shenyang Northern Hospital Wang Shouli Han Yalin.
Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.
Safety and Efficacy of Intravenous Enoxaparin in Elective Percutaneous Coronary Intervention: An International Randomised Evaluation One year follow-up.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
Baseline Characteristics Current or Former Smoker Diabetic Hypertension 25.7 Prior MI Prior Heart Failure.
Bleeding in Patients Undergoing Percutaneous Coronary Interventions: A Risk Model From 302,152 Patients in the NCDR. Sameer K. Mehta MD, Andrew D. Frutkin.
on behalf of the TOTAL Investigators
A randomized comparison of RadIal Vs. femorAL access for coronary intervention in ACS (RIVAL) SS Jolly, S Yusuf, J Cairns, K Niemela, D Xavier, P Widimsky,
Safety and Efficacy of Switching from Either UFH or Enoxaparin Plus a GP IIb/IIIa Inhibitor to Bivalirudin Monotherapy in Patients with Non-ST Elevation.
Ramin Ebrahimi, MD University of California Los Angeles/ Greater Los Angeles VA Medical Center Implications of Preoperative Thienopyridine Use Prior to.
Disclosure Statement of Financial Interest
Major Bleeding is Associated with Increased 30-Day Mortality and Ischemic Complications in Patients with Non-ST Elevation Acute Coronary Syndromes Undergoing.
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Bivalirudin: Myths vs Reality? Dr Reman McDonagh Nycomed UK Ltd Conflict of Interest: Senior Manager working for Nycomed UK Ltd.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Major Bleeding is Associated with Increased One-Year Mortality and Ischemic Events in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary.
Gender Differences in Long-Term Outcomes Following PCI of Patients with Non-ST Elevation ACS: Results from the ACUITY Trial Alexandra J. Lansky on behalf.
The Effect of Cangrelor and Access Site on Ischemic and Bleeding Events – Insights from CHAMPION PHOENIX J. Antonio Gutierrez, MD, MHS, Robert A. Harrington,
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
Duration Safety and Efficacy of Bivalirudin in patients undergoing PCI: The impact of duration of infusion in ACUITY trial Dr. David Cox Lehigh Valley.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Rivaroxaban in stable peripheral or carotid artery disease
Pros and Cons of Radial Access
Rivaroxaban in stable peripheral or carotid artery disease
Impact of Radial Access on Bleeding
Prof. Yasser Baghdady, MD Professor of Cardiology Cairo University
CORONARY: The Coronary Artery Bypass Grafting Surgery Off or On Pump
Women, Bleeding, and Coronary Intervention
Why Radial Access Should be the Default for Women undergoing PCI?
The TREAT Study: Can Devices Lower Bleeding Rates?
Is There a Role for Aspiration in STEMI?
Radial vs Femoral Access in ACS Patients
POISE-2 PeriOperative ISchemic Evaluation-2 Trial
Sunil V. Rao MD The Duke Clinical Research Institute
Seeking the Optimal Upstream Therapy for Patients with ACS: Fondaparinux- Low Bleeding Rate and Low Cost Sanjit S. Jolly MD, Interventional Cardiologist,
Dr. Harvey White on behalf of the ACUITY investigators
The Time Dependence of Anti-thrombin Initiation in Patients with Non-ST-segment –elevation Acute Coronary Syndrome: Subgroup Analysis form the ACUITY.
Impact of clopidogrel loading dose on the safety and effectiveness of bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction:
Implications of Preoperative Thienopyridine Use
What oral antiplatelet therapy would you choose?
Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial Renato D. Lopes, MD, PhD on behalf of the.
A randomized comparison of RadIal Vs
OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)
Atlantic Cardiovascular Patient Outcomes Research Team
Bleeding and Outcomes OASIS Registry, OASIS - 2, CURE (n=34,146) Death
Presentation transcript:

A randomized comparison of RadIal Vs. femorAL access for coronary intervention in ACS (RIVAL) SS Jolly, S Yusuf, J Cairns, K Niemela, D Xavier, P Widimsky, A Budaj, M Niemela, V Valentin, BS Lewis, A Avezum, PG Steg, SV Rao, P Gao, R Afzal, CD Joyner, S Chrolavicius, SR Mehta on behalf of the RIVAL Steering committee

R I V A LDisclosures Funded by: Sanofi-Aventis and Bristol-Myers Squibb (through CURRENT) Sanofi-Aventis and Bristol-Myers Squibb (through CURRENT) Population Health Research Institute Population Health Research Institute Canadian Network and Centre for Trials Internationally (CANNeCTIN, an initiative of Canadian Institutes of Health Research) Canadian Network and Centre for Trials Internationally (CANNeCTIN, an initiative of Canadian Institutes of Health Research)

R I V A L Bleeding is associated with Death and Ischemic Events Eikelboom JW et al. Circulation 2006;114(8): HR 5.37 ( ) HR 4.44 ( ) HR 6.46 ( )

R I V A L Prior Meta-analysis of 23 RCTs of Radial vs. Femoral (N=7030) Transradial betterTransfemoral better 1.0 PCI Procedure Failure Death Death, MI or stroke Major bleeding 1.31 ( ) 0.74 ( ) 0.71 ( ) 0.27 ( ) Jolly SS, et al. Am Heart J 2009;157:

R I V A L RIVAL Study Objective - To determine if Radial vs. Femoral access for coronary angiography/PCI can reduce the composite of death, MI, stroke or non-CABG major bleeding in ACS patients

R I V A L NSTE-ACS and STEMI (n=7021) Radial Access (n=3507) Femoral Access (n=3514) Primary Outcome: Death, MI, stroke or non-CABG-related Major Bleeding at 30 days Randomization RIVAL Study Design Key Inclusion: Intact dual circulation of hand required Interventionalist experienced with both (minimum 50 radial procedures in last year) Jolly SS et al. Am Heart J. 2011;161:

R I V A L Study Outcome Definitions Major Bleeding (CURRENT/ OASIS 7) Fatal > 2 units of Blood transfusion Hypotension requiring inotropes Requiring surgical intervention ICH or Intraocular bleeding leading to significant vision loss Major Vascular Access Site Complications Large hematoma Pseudoaneurysm requiring closure AV fistula Other vascular surgery related to the access site

R I V A L Final Recruitment RIVAL Stand-Alone After CURRENT N= 3190 RIVAL Total N=7,021 RIVAL sub-study during OASIS 7/CURRENT N= Follow-up complete in 99.9% CURRENT-OASIS 7. N Engl J Med. 2010;363: Mehta SR, et al. Lancet. 2010; 376:

R I V A L Participating Countries Middle East/Israel 239 Australia and New Zealand 64 North America 1614 South America 423 Asia 1117 Europe 3564

R I V A L Baseline Characteristics Radial (n =3507) Femoral (n =3514) Mean Age (years)62 Male (%) Diabetes (%) Diagnosis at presentation UA (%) NSTEMI (%) STEMI (%)

R I V A L Therapies - Initial Hospitalization Therapies - Initial Hospitalization Radial (n=3507) % Femoral (n=3514) % ASA Clopidogrel LMWH UFH Fondaparinux Bivalirudin GP IIb IIIa inhibitors PCI CABG8.88.3

R I V A L Operator Volume Procedure Characteristics Radial (n=3507) Femoral (n=3514) HR (95% CI) P value Operator Annual Volume PCI/year (median, IQR) 300 (190, 400) Percent Radial PCI ( median, IQR) 40 (25,70) PCI Success ( )0.83 Vascular closure devices used in 26% of Femoral group

R I V A L Primary and Secondary Outcomes Radial (n=3507) % Femoral (n=3514) % HR 95% CI P Primary Outcome Death, MI, Stroke, Non-CABG Major Bleed Secondary Outcomes Death, MI, Stroke Non-CABG Major Bleeding

R I V A L Other Outcomes Radial (n=3507) % Femoral (n=3514) % HR 95% CI P Death MI Stroke Stent Thrombosis * Post Hoc analysis

R I V A L Other Outcomes Radial (n=3507) % Femoral (n=3514) % HR 95% CI P Major Vascular Access Site Complications < TIMI Non-CABG Major Bleeding ACUITY Non-CABG Major Bleeding* < * Post Hoc analysis

R I V A L Other Outcomes Radial (n=3507) Femoral (n=3514) P Access site Cross-over (%) < PCI Procedure duration (min) Fluoroscopy time (min) < Persistent pain at access site >2 weeks (%) Patient prefers assigned access site for next procedure (%) 9049<0.0001

R I V A L Access Site Major Bleeds *All access site major bleeds actually occurred at femoral arterial site (in radial group due to cross-over or IABP) HR 0.50 (95% CI ) *

<75 ≥75 Female Male < >35 ≤ >142.5 Lowest Tertile Middle Tertile Highest Tertile NSTE-ACS STEMI Age Gender BMI Radial PCI Volume/year by Operator Radial PCI Volume by Centre Clinical Diagnosis Overall Radial better Femoral better Hazard Ratio(95% CI) Interaction p-value Death, MI, Stroke or non-CABG major Bleed Subgroups: Primary Outcome R I V A L

Radial better Femoral better Hazard Ratio(95% CI) High Medium Low High Medium Low High Medium Low High Medium Low High Medium Low Interaction p-value HR (95% CI) Primary Outcome Death, MI or stroke Non CABG Major Bleed Major Vascular Complications Access site Cross-over Results stratified by High*, Medium* and Low* Volume radial Centres R I V A L No significant interaction by Femoral PCI center volume Tertiles of Radial PCI Centre Volume/yr *High (>146 radial PCI/year/ median operator at centre), Medium (61-146), Low (≤60)

NSTE/ACS STEMI NSTE/ACS STEMI NSTE/ACS STEMI NSTE/ACS STEMI NSTE/ACS STEMI Radial better Femoral better Hazard Ratio(95% CI) Interaction p-value 2NRadial Femoral % Primary Outcome Death, MI or stroke Death Non CABG Major Bleed Major Vascular Complications Outcomes stratified by STEMI vs. NSTEACS R I V A L

Radial better Femoral better Hazard Ratio(95% CI) Pre-RIVAL RIVAL Combined Pre-RIVAL RIVAL Combined Pre-RIVAL RIVAL Combined Pre-RIVAL (Radial Expert Centre trials)* RIVAL (highest radial PCI centre tertile) Combined Heterogeneity p-value Radial(%) Femoral(%) Non-CABG Major Bleeds Major Vascular Access Complication Death,MI or Stroke Death, MI or Stroke (Radial Experts) Updated Meta-analysis of RCTs < P-value *Radial Expert Centres defined as centres default approach radial or known expert radial centre

R I V A LConclusion No significant difference in primary outcome of death, MI, stroke or non-CABG major bleeding No significant difference in primary outcome of death, MI, stroke or non-CABG major bleeding Rates of Primary outcome appeared to be lower in Radial group in high volume radial centres and STEMI Rates of Primary outcome appeared to be lower in Radial group in high volume radial centres and STEMI Radial had fewer major vascular complications but similar PCI success Radial had fewer major vascular complications but similar PCI success

R I V A LImplications Both radial and femoral approaches are safe and effective Both radial and femoral approaches are safe and effective The reduction in vascular complications may be a reason to use radial The reduction in vascular complications may be a reason to use radial With increasing experience the radial approach may be associated with better outcomes With increasing experience the radial approach may be associated with better outcomes

R I V A LAcknowledgements RIVAL Program Investigators from 158 sites in 32 countries Steering Committee S.S. Jolly (PI)S.R. Mehta (PI) S. Yusuf (Chair)C.D. Joyner (Adjudication Chair) S. ChrolaviciusM. Keltai A. AvezumF. Lanas A. BudajB. Lewis J. CairnsK. Niemela R. Diaz S.V. Rao V. DzavikP. G. Steg M.G. Franzosi V. Valentin C. B. Granger P. Widimsky D. Xavier DMC P. Sleight (Chair)) D. R. Holmes Jr. J.L. Anderson D.E. Johnstone D. DeMets J. Hirsh Project Office Study Team S. Chrolavicius (Project Manager) B. Jedrzejowski (Research Coordinator) M. Lawrence (Events Adjudication Coordinator) R. Manojlovic, L. Mastrangelo, E. Pasadyn, C. Agrippa, M. McClelland, (former ) C. Cramp, C. Horsman, A. Robinson, L. Blake, W. Chen, S. Diodato, A. Lehmann, T. Sovereign, L.Wasala Statisticians and Biometrics R. Afzal (IDMC-Associated) P. Gao L. Xu X. Yang E. Dai